Objectives Integrase strand transfer inhibitors (INSTIs) have been recently recommended as
the preferred first-line option for antiretroviral treatment initiators in low-and middle-income …

Abstract Objectives In Cameroon, the integrase (IN) strand transfer inhibitor (INSTI)
dolutegravir was recently introduced for the treatment of HIV-1 infection. Since pretreatment …

Objectives To investigate the prevalence and patterns of major and accessory resistance
mutations associated with integrase strand transfer inhibitors (INSTIs), across diverse HIV-1 …

With the widespread use of Integrase strand transfer inhibitors (INSTIs), surveillance of HIV-
1 pretreatment drug resistance is critical in optimizing antiretroviral treatment efficacy …

Background Monitoring the trends of pre-treatment drug resistance (PDR) and resistance-
associated mutations (RAMs) among antiretroviral-naïve people with HIV (PWH) is important …

Objective Assessing the prevalence of resistance and drug resistance mutations (DRMs) in
HIV/AIDS patients towards integrase strand transfer inhibitors (INSTIs), particularly the 2nd …

Background With the widespread use of integrase strand transfer inhibitors (INSTIs) in the
clinical setting, transmission of INSTIs-resistance mutations may increase. Data regarding …

ABSTRACT Objectives In Eastern Europe, HIV-1 transmitted drug resistance (TDR) data,
especially in the integrase (IN) region, are limited. In Estonia, INSTI (integrase strand …

Background and Objective: Integrase strand transfer inhibitors (INSTIs) are currently the
standard of practice for first-line HIV therapy for most patients. We evaluated the mutations …

The World Health Organization (WHO) has put forth recommendations for the use of
integrase (IN) strand transfer inhibitors (INSTIs) to be part of the first-line combination …